Prognostic impact of tumor-specific insulin-like growth factor binding protein 7 (IGFBP7) levels in breast cancer: a prospective cohort study

The prognostic impact of insulin-like growth factor binding protein 7 (IGFBP7) in breast cancer is unclear. Host factors, including lifestyle, anthropometry and metabolic profile, might influence tumor-specific IGFBP7. This study aimed to investigate whether IGFBP7 levels and messenger ribonucleic acid (mRNA) expression are associated with the patient and tumor characteristics and prognosis in breast cancer. Patients with primary breast cancer in Lund, Sweden, were included preoperatively in the study between 2002 and 2012 (n = 1018). Tumor-specific IGFBP7 protein levels were evaluated with immunohistochemistry using tissue microarrays in tumors from 878 patients. IGFBP7 mRNA expression and its corresponding clinical data were obtained from The Cancer Genome Atlas and analyzed for 809 patients. llimor-specific IGFBP7 protein levels were categorized based on Histo 300 scores into IGFBP7(low) (6.2%), IGFBP7(intermediate) (75.7%) and IGFBP7(high) (18.1%). Both low IGFBP7 protein levels and mRNA expression were associated with less aggressive tumor characteristics. Overall, IGFBP7(low )conferred low recurrence risk. The prognostic impact of IGFBP7(high) varied according to any alcohol consumption and tamoxifen treatment. IGFBP7(high) was associated with low recurrence risk in alcohol consumers but high recurrence risk in alcohol abstainers (P-interaction = 0.039). Moreover, the combination of IGFBP7(high) and estrogen receptor-positive tumors was associated with low recurrence risk only in tamoxifen-treated patients (P-interaction = 0.029). To conclude, IGFBP7(low) might be a good, independent prognosticator in breast cancer. The prognostic impact of IGFBP7(high)( )depends on host factors and treatment. IGFBP7 merits further investigation to confirm whether it could be a suitable biomarker for treatment selection. [GRAPHICS] .

Automated summary

The prognostic impact of IGFBP7 in breast cancer remains unclear, with low levels associated with less aggressive tumor characteristics. The prognostic impact of IGFBP7 high levels varies based on host factors and treatment. Further investigation is needed to confirm IGFBP7 as a potential biomarker for treatment selection.